Does Rallies show Form 4 insider transactions for JNJ?

Yes. Rallies tracks JNJ insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is JNJ research on Rallies investment advice?

No. Rallies provides research, data, and educational context for JNJ. It does not provide personalized investment advice.

JNJ (Johnson & Johnson) Stock Analysis - Insider Trades

Johnson & Johnson (JNJ) is a publicly traded Healthcare sector company. As of May 20, 2026, JNJ trades at $229.30 with a market cap of $551.06B and a P/E ratio of 26.42. JNJ moved -0.35% today. Year to date, JNJ is +12.24%; over the trailing twelve months it is +49.24%. Its 52-week range spans $140.68 to $251.71. Analyst consensus is buy with an average price target of $264.75. Rallies surfaces JNJ's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading JNJ stock inside the company?

Recent JNJ insider activity includes Decker Robert J sold 4.08K, Schmid Timothy sold 1.32K, Schmid Timothy sold 13.63K, Schmid Timothy sold 9.00K, and Swanson James D. sold 20.52K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

JNJ Key Metrics

Key financial metrics for JNJ
Metric	Value
Price	$229.30
Market Cap	$551.06B
P/E Ratio	26.42
EPS	$8.73
Dividend Yield	1.34%
52-Week High	$251.71
52-Week Low	$140.68
Volume	3.37M
Avg Volume	0
Revenue (TTM)	$96.36B
Net Income	$21.04B
Gross Margin	67.82%

Recent JNJ Insider Trades

Decker Robert J sold 4.08K (~$1.01M) on Feb 27, 2026.
Schmid Timothy sold 1.32K (~$324.76K) on Feb 20, 2026.
Schmid Timothy sold 13.63K (~$3.33M) on Feb 18, 2026.
Schmid Timothy sold 9.00K (~$2.20M) on Feb 18, 2026.
Swanson James D. sold 20.52K (~$4.98M) on Feb 17, 2026.

Latest JNJ News

Johnson & Johnson Reports Darzalex, Tremfya Growth with AAA Rating, 64-Year Dividend Streak — May 19, 2026
Nanoradioenhancer JNJ-1900 Posts 85.7% Response Rate; Ebola Emergency Declared — May 17, 2026
Johnson & Johnson Stock Falls 3.5% as Survey Finds Over 90% of Bladder Cancer Patients Report Severe Impacts — May 14, 2026
JNJ jumps as Leerink upgrades to Outperform and lifts target to $265 — May 13, 2026
Johnson & Johnson Secures AAA Rating, One of Only Two U.S. Firms — May 13, 2026

JNJ Analyst Consensus

18 analysts cover JNJ: 0 strong buy, 12 buy, 6 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $264.75.

Common questions about JNJ

Who is trading JNJ stock inside the company?: Recent JNJ insider activity includes Decker Robert J sold 4.08K, Schmid Timothy sold 1.32K, Schmid Timothy sold 13.63K, Schmid Timothy sold 9.00K, and Swanson James D. sold 20.52K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for JNJ?: Yes. Rallies tracks JNJ insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is JNJ research on Rallies investment advice?: No. Rallies provides research, data, and educational context for JNJ. It does not provide personalized investment advice.